- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: M.Nardi ITALY
Co Author(s): J. García-Feijoó M. Rau P. Guguchkova T. Ianchulev
Back to previous
Evaluate the safety and outcomes of supraciliary micro-stent implantation as a treatment for open-angle glaucoma.
Multi-site clinical study in Europe and Canada.
In a prospective, multicenter interventional case series (DUETTE study),the CyPass Micro-Stent (Transcend Medical, Inc, Menlo Park, CA) was implanted into the supraciliary space through a 1.5 mm incision in 65 subjects for whom medical therapy was insufficient to control intraocular pressure. Safety data, including adverse events, complications, intraocular pressure, and medications, are reported up to 12 months postoperative.
The majority of subjects (68%) were on 2 or more medications preoperative and all had a baseline medicated IOP ? 21 mmHg. Mean medicated IOP at baseline was 24.3 mmHg. There were no peri- or postoperative cases of suprachoroidal hemorrhage, bleb-related complications, retinal complications or hypotony maculopathy. At 12 months after surgery, mean IOP was 15.2 mmHg with a 41% reduction in IOP from baseline. 86% of patients had a >20% reduction in IOP with a concomitant reduction, or no change, in IOP-lowering medications.
The supraciliary CyPass Micro-Stent provided safe and sustained IOP reduction in patients with primary open-angle glaucoma.
... is employed by a for-profit company with an interest in the subject of the presentation, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented